Survey: Most pharmaceutical execs foresee more M&A

A survey of top executives of U.S. drugmakers indicates mergers and acquisitions should pick up in the next couple of years, as companies aim to offset rising generic competition. The survey by audit and advisory consultants KPMG LLP found 83 percent of pharmaceutical executives believe their company likely will be a buyer or a seller [...] [...]